The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Travere Therapeutics (NASDAQ:TVTX) executives highlighted a first-quarter marked by an FDA approval, record demand for ...

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

(TVTX) on Monday reported a loss of $37.1 million in its first quarter.

Travere Therapeutics Inc. (NASDAQ:TVTX) reported first quarter results that fell short of Wall Street expectations, with both earnings and revenue missing analyst ...

Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...

Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five ...

In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Merck & Company, with a price target of $140.00. Claim 55% Off TipRanks. Unlock hedge fund-l ...

Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...

Johnson & Johnson will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026.

Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...